Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245282 · ClinicalTrials.gov registry record
Contrast Enhanced MRI of the Prostate
A clinical trial, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 14
- Enrollment target
NCT02245282: Completed study, sponsored by OHSU Knight Cancer Institute.
NCT02245282 is a clinical trial that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02245282 has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
Prostate cancer detection and disease progression monitoring relies on systematic multi-core biopsies. Minimal invasive imaging capacities for lesion targeting and monitoring are badly needed. The purpose of this study is to determine if a new MRI technique can identify and monitor prostate disease progression. If so biopsy core number can be reduced to as small as one, and frequency for biopsy repeat can be reduced. The new technique is about a new way of analyzing the pictures taken as part of prostate MRI exam. This part is called dynamic contrast-enhanced MRI. It involves an injection of contrast reagent (or dye) through the arm vein during a time period when prostate MRI pictures are continuously taken.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-02-10 |
| Est. Completion | 2018-12-12 |
What the finished NCT02245282 record still lists
NCT02245282 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02245282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02245282 about?
NCT02245282 is a clinical study titled "Contrast Enhanced MRI of the Prostate". Prostate cancer detection and disease progression monitoring relies on systematic multi-core biopsies. Minimal invasive imaging capacities for lesion targeting and monitoring are badly needed. The purpose of this study is to determine if a new MRI technique can identify and monitor prostate disease ...
What is the current status of trial NCT02245282?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2017-02-10. Estimated completion is 2018-12-12.
Who is sponsoring clinical trial NCT02245282?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy